Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 44
Filtrar
1.
Trop Doct ; 49(4): 268-270, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31208292

RESUMEN

Postscabies prurigo (PSP) is caused by a delayed hypersensitivity reaction to antigens of the mite. Treatment is based on potent topical or intralesional corticosteroids. We present the results of a study on the effectiveness of a topical combination of diflucortolone and chlorquinaldol. Eighteen African patients who had been previously affected by scabies and treated with permethrin were enrolled. The diagnosis of PSP was made by excluding other causes through microscopic examinations. All patients were treated with the drug combination by two applications daily for two weeks. The primary study objective was to evaluate the itch by a visual analogue scale (VAS) of 0-100. Fifteen patients (83.3%) could be evaluated. All reported improvements: from 86/100 at the start to 29/100 (-57/100) at the end of treatment. Chlorquinaldol, known as an antiseptic agent, demonstrated, according to results of this study, an important anti-itch action.


Asunto(s)
Clorquinaldol/uso terapéutico , Diflucortolona/uso terapéutico , Prurigo/tratamiento farmacológico , Refugiados , Escabiosis/tratamiento farmacológico , Adolescente , Adulto , África , Antiinfecciosos/uso terapéutico , Quimioterapia Combinada , Femenino , Glucocorticoides/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Prurigo/etiología , Escabiosis/complicaciones , Resultado del Tratamiento , Adulto Joven
2.
J Coll Physicians Surg Pak ; 29(2): 115-118, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30700347

RESUMEN

OBJECTIVE: To compare the effects of chlorquinaldol-promestriene vaginal tablets and opin suppositories on serum inflammatory factors and immune function in patients with chronic cervicitis complicated with HPV infection. STUDY DESIGN: An experimental study. PLACE AND DURATION OF STUDY: Department of Gynaecology and Obstetrics, People's Hospital of Zhouzhi County, Shaanxi, China, from January 2016 to June 2017. METHODOLOGY: A total of 98 patients with chronic cervicitis complicated with HPV infection were randomly divided into the observation group and the control group with 49 cases in each group. Control group received vaginal administration of opin suppositories, and the observation group received chlorquinaldol-promestriene vaginal tablets. After treatment, the HPV-DNA negative conversion rate, levels of serum inflammatory factors (IL-1, IL-6 and hs-CRP) and indices of immune function (CD3 +,CD4 +, CD8 + and CD4 +/CD8 +) were compared between the two groups. RESULTS: At 6 and 9 months after treatment, the HPV-DNA negative conversion rate in the observation group was higher than that in the control group (p=0.001 and p<0.001, respectively). At 6 months after treatment, serum IL-1, IL-6, and hs-CRP levels in the observation group were lower than those in the control group (p<0.001, p=0.001 and p=0.002, respectively); serum CD3 +,CD4 +, CD8 + and CD4 +/CD8 + levels in the observation group were higher than those in the control group (all p<0.001). CONCLUSION: Chlorquinaldol-promestriene vaginal tablet is more effective than opin suppository in the treatment of patients with chronic cervicitis complicated with HPV infection. It can effectively improve the HPV-DNA negative conversion rate, reduce the level of serum inflammatory factors and improve the body's immune function.


Asunto(s)
Clorquinaldol/uso terapéutico , Estradiol/análogos & derivados , Infecciones por Papillomavirus/tratamiento farmacológico , Cervicitis Uterina/tratamiento farmacológico , Cervicitis Uterina/virología , Administración Intravaginal , Adulto , Anciano , Biomarcadores/sangre , Distribución de Chi-Cuadrado , Enfermedad Crónica , ADN Viral/sangre , Combinación de Medicamentos , Ensayo de Inmunoadsorción Enzimática , Estradiol/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Infecciones por Papillomavirus/diagnóstico , Medición de Riesgo , Supositorios , Resultado del Tratamiento , Cervicitis Uterina/diagnóstico
3.
Akush Ginekol (Sofiia) ; 46(1): 46-7, 2007.
Artículo en Búlgaro | MEDLINE | ID: mdl-17469464

RESUMEN

The data of 30 nonpregnant women in reproductive age BV treated with Gynalgin were presented. On clinical and microbiological indicator Gynalgin showed a good effect on BV-associated microorganisms (80%). Only one of the cases of BV was not affected (4%). With nixed infection of BV and Candida we established clinical improvement and recovery of Lactobacillus spp. In 66.6%, but in all cases on Candida is not effect. We consider that Gynalgin is still one more easily applicable and clinically effective opportunity for treatment of BV.


Asunto(s)
Antiinfecciosos/uso terapéutico , Candidiasis Vulvovaginal/tratamiento farmacológico , Clorquinaldol/uso terapéutico , Metronidazol/uso terapéutico , Vaginosis Bacteriana/tratamiento farmacológico , Administración Intravaginal , Antiinfecciosos/administración & dosificación , Candidiasis Vulvovaginal/microbiología , Clorquinaldol/administración & dosificación , Esquema de Medicación , Combinación de Medicamentos , Femenino , Humanos , Metronidazol/administración & dosificación , Comprimidos , Resultado del Tratamiento , Vaginosis Bacteriana/microbiología
4.
Rev. obstet. ginecol. Venezuela ; 54(2): 97-9, 1994. ilus, tab
Artículo en Español | LILACS | ID: lil-234625

RESUMEN

Se trataron 203 casos de coalescencia de labios menores con crema de valerianato de difucortolona y clorquinaldol. Los resultados obtenidos en todas las pacientes fueron los esperados


Asunto(s)
Humanos , Femenino , Recién Nacido , Lactante , Preescolar , Diflucortolona/uso terapéutico , Adherencias Tisulares/terapia , Clorquinaldol/uso terapéutico , Clítoris/anomalías , Labio/patología
6.
Acta Vet Hung ; 39(3-4): 127-35, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1838458

RESUMEN

The sensitivity of ten Bordetella bronchiseptica and ten Pasteurella multocida strains, each isolated from cases of atrophic rhinitis (AR), was examined in tube dilution test. Getroxel, chlorquinaldol and oxytetracycline and the former two ones combined with trimethoprim inhibited the growth of both species in vitro. The minimum inhibitory and the minimum bactericidal concentration was less than 0.5 microgram/ml. When efficacy was tested in SPF in the group fed a combination of Getroxel, chlorquinaldol and oxytetracycline (60 mg, 240 mg and 360 mg/kg of feed, respectively), P. multocida disappeared from the nasal cavity by the end of a 30-day treatment. B. bronchiseptica was reisolated in low numbers from 2 out of 9 piglets. The daily body mass gain was by 7.9% higher and the feed conversion rate was by 19% better than in the control group. After slaughter, only mild signs of AR were seen in 3 out of 9 piglets treated with the above-mentioned drug combination, while in the control group severe lesions were observed in 8 out of 9 pigs. In treated commercial herds P. multocida disappeared from the nasal cavity of the piglets by the end of the treatment (42nd day of life), but the B. bronchiseptica strains could not be completely eliminated. Due to the treatment, mortality between 2 and 6 weeks of age decreased by 0.8-7.6%. Daily body mass gain was, on the average, 16.4% higher, the amount of feed needed for 1 kg body mass gain was by 15.3% lower and the duration of fattening was by 30.8 days shorter than in the control groups.


Asunto(s)
Carbadox/uso terapéutico , Clorquinaldol/uso terapéutico , Oxitetraciclina/uso terapéutico , Rinitis Atrófica/veterinaria , Enfermedades de los Porcinos/tratamiento farmacológico , Animales , Bordetella bronchiseptica/efectos de los fármacos , Pasteurella multocida/efectos de los fármacos , Rinitis Atrófica/tratamiento farmacológico , Organismos Libres de Patógenos Específicos , Porcinos
8.
Drugs ; 36 Suppl 5: 24-33, 1988.
Artículo en Inglés | MEDLINE | ID: mdl-3254827

RESUMEN

More than 10 years ago, diflucortolone valerate (Nerisone, Nerisona) was introduced in Germany and soon after in Asian countries in a concentration of 0.1% in cream, ointment and fatty ointment bases. 897 patients were included in the first Southeast Asian multicentre trial with these 3 formulations, and good efficacy and tolerability combined with a rapid onset of effect were shown. These results were confirmed later in Indonesia in an extended follow-up trial which included 1295 patients. A combination of 0.1% diflucortolone valerate with 1.0% chlorquinaldol was introduced after a multicentre Southeast Asian trial involving 8668 patients with inflammatory or allergic skin conditions for which a supplementary anti-infective treatment, for prophylaxis or therapy, was considered to be indicated. Excellent results were obtained in terms of efficacy, tolerability and cosmetic properties. A randomised double-blind trial comparing this preparation with a so-called 'shotgun' combination containing 0.05% betamethasone 17-valerate, 0.1% gentamicin, 1.0% tolnaftate and 1.0% clioquinol in 288 patients in the Philippines resulted in a better efficacy for the diflucortolone preparation in the 80 patients with bacterially or mycotically infected skin diseases. A 0.3% concentration of diflucortolone valerate was developed and introduced as a high potency topical corticosteroid. A trial in the Philippines which involved 143 patients with mostly severe chronic recurrent and resistant corticosteroid-responsive skin disease confirmed a pronounced clinical efficacy with a low incidence of side effects. For the treatment of inflammatory or eczematised dermatomycosis. 0.1% diflucortolone was combined with 1.0% isoconazole nitrate (Travocort). In a randomised double-blind study of 294 patients in Thailand, this preparation was compared with a plain 1.0% clotrimazole formulation. The results were significantly better for the diflucortolone plus isoconazole nitrate combination in terms of remission of symptoms, and after 1 week the mycological cure rates were also better, as shown in potassium hydroxide and culture investigations. It is concluded, therefore, that diflucortolone valerate in the available galenic bases and in effective combinations with other agents has been proven in extensive clinical trials to be a valuable therapeutic tool in dermatological practice.


Asunto(s)
Diflucortolona/análogos & derivados , Fluocortolona/análogos & derivados , Enfermedades de la Piel/tratamiento farmacológico , Asia , Clorquinaldol/uso terapéutico , Dermatomicosis/tratamiento farmacológico , Dermatomicosis/microbiología , Diflucortolona/farmacología , Diflucortolona/uso terapéutico , Humanos , Miconazol/análogos & derivados , Miconazol/uso terapéutico , Pomadas
12.
Acta Obstet Gynecol Scand ; 60(3): 233-5, 1981.
Artículo en Inglés | MEDLINE | ID: mdl-7270090

RESUMEN

In an attempt to reduce the incidence of infectious complications after first trimester legal abortion 199 healthy, early pregnant women were treated with chloroquinaldol (SterosanR vaginal jelly) during six days before their vacuum aspiration. A group of 291 women served as control. In the treatment group 18 women (9%) had a postoperative gynecological infection while this condition was found in 37 women (12.8%) in the control group. This difference is not statistically significant. The authors conclude that preoperative prophylactic treatment with Sterosan vaginal jelly does not seem to reduce postoperative infectious complications after first trimester legal abortions.


Asunto(s)
Aborto Inducido , Clorquinaldol/uso terapéutico , Dilatación y Legrado Uterino/efectos adversos , Enfermedad Inflamatoria Pélvica/prevención & control , Legrado por Aspiración/efectos adversos , Cremas, Espumas y Geles Vaginales , Adulto , Femenino , Humanos , Embarazo
15.
Z Hautkr ; 53(13): 453-8, 1978 Jul 01.
Artículo en Alemán | MEDLINE | ID: mdl-150142

RESUMEN

Bi-Nerisone cream and a control preparation, also in the form of a cream, have been clinically tested on 343 patients by means of a double blind study. Equilvalent results were obtained without registering any significant statistical differences, a finding, however, proving to be of great importance as Bi-Nerisone only contains two active substances (Diflucortolone valerat + Chlorquinaldol), whereas the control preparation contains a total of four (Betamethasone valerate + Gentamycin + Tolnaftate + Clioquinol).


Asunto(s)
Clorquinaldol/uso terapéutico , Dermatitis/tratamiento farmacológico , Fluocortolona/uso terapéutico , Pregnadienodioles/uso terapéutico , Valerato de Betametasona/uso terapéutico , Ensayos Clínicos como Asunto , Clioquinol/uso terapéutico , Método Doble Ciego , Combinación de Medicamentos , Fluocortolona/análogos & derivados , Gentamicinas/uso terapéutico , Humanos , Pomadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA